

8-K/A
1
d8ka.txt
FORM 8-K/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 18, 1999

SHEFFIELD PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware

1-12584

13-3808303

(State or other jurisdiction
of incorporation)

(Commission
File Number)
Number)

(I.R.S. Employer
Identification

14528 South Outer Forty Road, St. Louis, Missouri 63017

(Address of Principal executive offices) (Zip Code)

(314) 579-9899

Registrant's telephone number, including area code

(Former Name or Former Address; if Changed Since Last Report)

Item 5. Other Events.

This amendment is being submitted to file amended forms of Exhibits 10.25,

10.26, 10.27 and 10.28, previously filed in the registrant's Current Report on Form 8-K on November 2, 1999, which have been revised to include certain information previously omitted which is no longer the subject of a confidential treatment request made by the registrant.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

- (10.25) Securities Purchase Agreement, dated as of October 18, 1999, by and between the Company and Elan (portions of this exhibit are omitted and were filed separately with the Securities and Exchange Commission pursuant to the Company's application requesting confidential treatment in accordance with Rule 24b-2 as promulgated under the Securities Exchange Act of 1934, as amended).

- (10.26) Subscription, Joint Development and Operating Agreement dated as of October 18, 1999 by and among Elan Pharma International Limited, Elan, the Company and Newco. (portions of this exhibit are omitted and were filed separately with the Securities and Exchange Commission pursuant to the Company's application requesting confidential treatment in accordance with Rule 24b-2 as promulgated under the Securities Exchange Act of 1934, as amended).

- (10.27) License Agreement dated October 19, 1999 by and between the Company and Newco (portions of this exhibit are omitted and were filed separately with the Securities and Exchange Commission pursuant to the Company's application requesting confidential treatment in accordance with Rule 24b-2 as promulgated under the Securities Exchange Act of 1934, as amended).

- (10.28) License Agreement dated October 20, 1999 by and between Elan Pharma International Limited and Newco (portions of this exhibit are omitted and were filed separately with the Securities and Exchange Commission pursuant to the Company's application requesting confidential treatment in accordance with Rule 24b-2 as promulgated under the Securities Exchange Act of 1934, as amended).

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHEFFIELD PHARMACEUTICALS INC.

Date: December 21, 2001

By: /s/ Scott Hoffman

Scott Hoffman
Vice President and
Chief Financial Officer